D
iabetes is a chronic illness that requires continuing medical care and patient self-management education to prevent acute complications and to reduce the risk of long-term complications. Diabetes care is complex and requires that many issues, beyond glycemic control, be addressed. A large body of evidence exists that supports a range of interventions to improve diabetes outcomes.
These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care. While individual preferences, comorbidities, and other patient factors may require modification of goals, targets that are desirable for most patients with diabetes are provided. These standards are not intended to preclude more extensive evaluation and management of the patient by other specialists as needed. For more detailed information, refer to Bode (Ed. The recommendations included are diagnostic and therapeutic actions that are known or believed to favorably affect health outcomes of patients with diabetes. A grading system (Table 1) , developed by the American Diabetes Association (ADA) and modeled after existing methods, was utilized to clarify and codify the evidence that forms the basis for the recommendations. The level of evidence that supports each recommendation is listed after each recommendation using the letters A, B, C, or E.
I. CLASSIFICATION AND DIAGNOSIS

A. Classification
In 1997, the ADA issued new diagnostic and classification criteria (4); in 2003, modifications were made regarding the diagnosis of impaired fasting glucose (IFG) (5). The classification of diabetes includes four clinical classes:
• Type 1 diabetes (results from ␤-cell destruction, usually leading to absolute insulin deficiency).
• Type 2 diabetes (results from a progressive insulin secretory defect on the background of insulin resistance).
• Other specific types of diabetes (due to other causes, e.g., genetic defects in ␤-cell function, genetic defects in insulin action, diseases of the exocrine pancreas, and drug or chemical induced).
• Gestational diabetes mellitus (GDM) (diagnosed during pregnancy).
B. Diagnosis
Criteria for the diagnosis of diabetes in nonpregnant adults are shown in Table 2 . Three ways to diagnose diabetes are available, and each must be confirmed on a subsequent day unless unequivocal symptoms of hyperglycemia are present.
Although the 75-g oral glucose tolerance test (OGTT) is more sensitive and modestly more specific than fasting plasma glucose (FPG) to diagnose diabetes, it is poorly reproducible and rarely performed in practice. Because of ease of use, acceptability to patients, and lower cost, the FPG is the preferred diagnostic test. It should be noted that the vast majority of people who meet diagnostic criteria for diabetes by OGTT, but not by FPG, will have an A1C value Ͻ7.0%. The use of the A1C for the diagnosis of diabetes is not recommended at this time.
Hyperglycemia not sufficient to meet the diagnostic criteria for diabetes is categorized as either IFG or impaired glucose tolerance (IGT), depending on whether it is identified through a FPG or an OGTT:
• IFG ϭ FPG 100 mg/dl (5.6 mmol/l) to 125 mg/dl (6.9 mmol/l) • IGT ϭ 2-h plasma glucose 140 mg/dl (7.8 mmol/l) to 199 mg/dl (11.0 mmol/l)
Recently, IFG and IGT have been officially termed "pre-diabetes." Both categories, IFG and IGT, are risk factors for future diabetes and cardiovascular disease (CVD).
Recommendations
• The FPG is the preferred test to diagnose diabetes in children and nonpregnant adults. (E) • The use of the A1C for the diagnosis of diabetes is not recommended at this time. (E)
II. SCREENING FOR DIABETES
There is a major distinction between diagnostic testing and screening. When an individual exhibits symptoms or signs of the disease, diagnostic tests are performed, and such tests do not represent screening. The purpose of screening is to identify asymptomatic individuals who are likely to have diabetes. Separate diagnostic tests using standard criteria are required after positive screening tests to establish a definitive diagnosis as described above.
Type 1 diabetes
Generally, people with type 1 diabetes present with acute symptoms of diabetes and markedly elevated blood glucose lev- • Evidence from a well-conducted multicenter trial • Evidence from a meta-analysis that incorporated quality ratings in the analysis • Compelling nonexperimental evidence, i.e., "all or none" rule developed by
Center for Evidence Based Medicine at Oxford Supportive evidence from well-conducted randomized controlled trials that are adequately powered including:
• Evidence from a well-conducted trial at one or more institutions • Evidence from a meta-analysis that incorporated quality ratings in the analysis B Supportive evidence from well-conducted cohort studies • Evidence from a well-conducted prospective cohort study or registry • Evidence from a well-conducted meta-analysis of cohort studies Supportive evidence from a well-conducted case-control study C Supportive evidence from poorly controlled or uncontrolled studies • Evidence from randomized clinical trials with one or more major or three or more minor methodological flaws that could invalidate the results • Evidence from observational studies with high potential for bias (such as case series with comparison to historical controls) • Evidence from case series or case reports Conflicting evidence with the weight of evidence supporting the recommendation E Expert consensus or clinical experience Table 2 -Criteria for the diagnosis of diabetes
1.
Symptoms of diabetes and a casual plasma glucose Ն200 mg/dl (11.1 mmol/l). Casual is defined as any time of day without regard to time since last meal. The classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss. OR 2.
FPG Ն126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h. OR 3.
2-h plasma glucose Ն200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water.
In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeat testing on a different day. The OGTT is not recommended for routine clinical use, but may be required in the evaluation of patients with IFG (see text) or when diabetes is still suspected despite a normal FPG as with the postpartum evaluation of women with GDM.
els. Because of the acute onset of symptoms, most cases of type 1 diabetes are detected soon after symptoms develop.
Widespread clinical testing of asymptomatic individuals for the presence of autoantibodies related to type 1 diabetes cannot be recommended at this time as a means to identify individuals at risk. Reasons for this include the following: 1) cutoff values for some of the immune marker assays have not been completely established in clinical settings; 2) there is no consensus as to what action should be taken when a positive autoantibody test result is obtained; and 3) because the incidence of type 1 diabetes is low, testing of healthy children will identify only a very small number (Ͻ0.5%) who at that moment may be "pre-diabetic." Clinical studies are being conducted to test various methods of preventing type 1 diabetes in high-risk individuals (e.g., siblings of type 1 diabetic patients). These studies may uncover an effective means of preventing type 1 diabetes, in which case targeted screening may be appropriate in the future.
Type 2 diabetes
Type 2 diabetes is frequently not diagnosed until complications appear, and approximately one-third of all people with diabetes may be undiagnosed. Individuals at high risk should be screened for diabetes and pre-diabetes. Criteria for testing for diabetes in asymptomatic, undiagnosed adults are listed in Table 3 . The effectiveness of early diagnosis through screening of asymptomatic individuals has not been determined (6). Screening should be carried out within the health care setting. Either an FPG test or 2-h OGTT (75-g glucose load) is appropriate. The 2-h OGTT identifies people with IGT, and thus more people who at increased risk for the development of diabetes and CVD. It should be noted that the two tests do not necessarily detect the same individuals (7). The FPG test is more convenient to patients, more reproducible, less costly, and easier to administer than the 2-h OGTT (4,5). Therefore, the recommended initial screening test for nonpregnant adults is the FPG.
The incidence of type 2 diabetes in children and adolescents has increased dramatically in the last decade. Consistent with screening recommendations for adults, only children and youth at increased risk for the presence or the development of type 2 diabetes should be tested (8) ( Table 4) .
The effectiveness of screening may also depend on the setting in which it is performed. In general, community screening, outside a health care setting, may be less effective because of the failure of people with a positive screening test to seek and obtain appropriate follow-up testing and care or, conversely, to ensure appropriate repeat testing for individuals who screen negative. That is, screening outside of clinical settings may yield abnormal tests that are never discussed with a primary care provider, low compliance with treatment recommendations, and a very uncertain impact on long-term health. Community screening may also be poorly targeted, i.e., it may fail to reach the groups most at risk and inappropriately test those at low risk (the worried well) or even those already diagnosed (9,10).
On the basis of expert opinion, screening should be considered by health care providers at 3-year intervals beginning at age 45 years, particularly in those with BMI Ն25 kg/m 2 . The rationale for this interval is that false negatives will be repeated before substantial time elapses, and there is little likelihood of an individual developing any of the complications of diabetes to a significant degree within 3 years of a negative screening test result. Testing should be considered at a younger age or be carried out more frequently in individuals who are overweight and have one or more of the other risk factors for type 2 diabetes.
Recommendations
• Screening to detect pre-diabetes (IFG or IGT) and diabetes should be considered in individuals Ն45 years of age, particularly in those with a BMI Ն25 kg/m 2 . Screening should also be con- 
III. DETECTION AND DIAGNOSIS OF GESTATIONAL DIABETES MELLITUS (GDM)
Risk assessment for GDM should be undertaken at the first prenatal visit. Women with clinical characteristics consistent with a high risk for GDM (those with marked obesity, personal history of GDM, glycosuria, or a strong family history of diabetes) should undergo glucose testing as soon as possible (11) . An FPG Ն126 mg/dl or a casual plasma glucose Ն200 mg/dl meets the threshold for the diagnosis of diabetes and needs to be confirmed on a subsequent day unless unequivocal symptoms of hyperglycemia are present. High-risk women not found to have GDM at the initial screening and average-risk women should be tested between 24 and 28 weeks of gestation. Testing should follow one of two approaches:
• One-step approach: perform a diagnostic 100-g OGTT • Two-step approach: perform an initial screening by measuring the plasma or serum glucose concentration 1 h after a 50-g oral glucose load (glucose challenge test [GCT] ) and perform a diagnostic 100-g OGTT on that subset of women exceeding the glucose threshold value on the GCT. When the twostep approach is used, a glucose threshold value Ն140 mg/dl identifies ϳ80% of women with GDM, and the yield is further increased to 90% by using a cutoff of Ն130 mg/dl.
Diagnostic criteria for the 100-g OGTT are as follows: Ն95 mg/dl fasting, Ն180 mg/dl at 1 h, Ն155 mg/dl at 2 h, and Ն140 mg/dl at 3 h. Two or more of the plasma glucose values must be met or exceeded for a positive diagnosis. The test should be done in the morning after an overnight fast of 8 -14 h. The diagnosis can be made using a 75-g glucose load, but that test is not as well validated for detection of at-risk infants or mothers as the 100-g OGTT. Low-risk status requires no glucose testing, but this category is limited to those women meeting all of the following characteristics:
• Age Ͻ25 years.
• Weight normal before pregnancy.
• Member of an ethnic group with a low prevalence of GDM.
• No known diabetes in first-degree relatives.
• No history of abnormal glucose tolerance.
• No history of poor obstetric outcome.
Recommendations
• Screen for diabetes in pregnancy using risk factor analysis and, if appropriate, use of an OGTT. (C) • Women with gestational diabetes should be screened for diabetes 6 weeks postpartum and should be followed up with subsequent screening for the development of diabetes or prediabetes. (E)
IV. PREVENTION/DELAY OF TYPE 2 DIABETES
Studies have been initiated in the last decade to determine the feasibility and benefit of various strategies to prevent or delay the onset of type 2 diabetes. Five well-designed randomized controlled trials have been reported (12) (13) (14) (15) (16) . The strategies shown to be effective in preventing diabetes relied on lifestyle modification or glucose-lowering drugs that have been approved for treating diabetes. In the Finnish study (12) , middleaged obese subjects with IGT were randomized to receive either brief diet and exercise counseling (control group) or intensive individualized instruction on weight reduction, food intake, and guidance on increasing physical activity (intervention group). After an average follow-up of 3.2 years, there was a 58% relative reduction in the incidence of diabetes in the intervention group compared with the control subjects.
In the Diabetes Prevention Program (DPP) (13), enrolled subjects were slightly younger and more obese but had nearly identical glucose intolerance compared with subjects in the Finnish study. About 45% of the participants were from minority groups (e.g., African American, Hispanic), and 20% were Ն60 years of age. Subjects were randomized to one of three intervention groups, which included the intensive nutrition and exercise counseling ("lifestyle") group or either of two masked medication treatment groups: the biguanide metformin group or the placebo group. The latter interventions were combined with standard diet and exercise recommendations. After an average follow-up of 2.8 years, a 58% relative reduction in the progression to diabetes was observed in the lifestyle group, and a 31% relative reduction in the progression of diabetes was observed in the metformin group compared with control subjects. On average, 50% of the lifestyle group achieved the goal of Ն7% weight reduction, and 74% maintained at least 150 min/week of moderately intense activity.
In the Da Qing Study (16) , men and women from health care clinics in the city of Da Qing, China, were screened with OGTT, and those with IGT were randomized by clinic to a control group or to one of three active treatment groups: diet only, exercise only, or diet plus exercise. Subjects were reexamined biannually, and after an average of 6 years follow-up the diet, exercise, and diet-plus-exercise interventions were associated with 31, 46, and 42% reductions in risk of developing type 2 diabetes, respectively. Two other studies, each using a different class of glucose-lowering agent, have shown a reduction in progression to diabetes with pharmacological intervention. In the Troglitazone in Prevention of Diabetes (TRIPOD) study (14) , Hispanic women with previous GDM were randomized to receive either placebo or troglitazone (a drug now withdrawn from commercial sale in the U.S. but belonging to the thiazolidinedione class). After a median follow-up of 30 months, troglitazone treatment was associated with a 56% relative reduction in progression to diabetes. In the STOP-NIDDM trial (15) , participants with IGT were randomized in a double-blind fashion to receive either the ␣-glucosidase inhibitor acarbose or a placebo. After a mean follow-up of 3.3 years, a 25% relative risk reduction in progression to diabetes, based on one OGTT, was observed in the acarbose-treated group compared with the placebo group. If this diagnosis was confirmed by a second OGTT, a 36% relative risk reduction was observed in the acarbose group compared with the placebo group.
Our knowledge of the early stages of hyperglycemia that portend the diagnosis of diabetes, and the recent success of major intervention trials, clearly show that individuals at high risk can be identified and diabetes delayed, if not prevented. The cost-effectiveness of intervention strategies is unclear, but the huge burden resulting from the complications of diabetes and the potential ancillary benefits of some of the interventions suggest that an effort to prevent diabetes is worthwhile.
Lifestyle modification
In well-controlled studies that included a lifestyle intervention arm, substantial efforts were necessary to achieve only modest changes in weight and exercise, but those changes were sufficient to achieve an important reduction in the incidence of diabetes. In the Finnish Diabetes Prevention Study, weight loss averaged 9.2 lb at 1 year, 7.7 lb after 2 years, and 4.6 lb after 5 years (12) ; "moderate exercise," such as brisk walking, for 30 min/day was suggested. In the Finnish study, there was a direct relationship between adherence with the lifestyle intervention and the reduced incidence of diabetes.
In the DPP (13), the lifestyle group lost ϳ12 lb at 2 years and 9 lb at 3 years (mean weight loss for the study duration was ϳ12 lb or 6% of initial body weight). In both of these studies, most of the participants were obese (BMI Ͼ30 kg/m 2 ). A low-fat (Ͻ25% fat) intake was recommended; if reducing fat did not produce weight loss to goal, calorie restriction was also recommended. Participants weighing 120 -174 lb (54 -78 kg) at baseline were instructed to follow a 1,200-kcal/day diet (33 g fat); participants weighing 175-219 lb (79 -99 kg) were instructed to follow a 1,500-kcal/ day diet (42 g fat); those 220 -249 lb (100 -113 kg) were instructed to follow an 1,800-kcal/day diet (50 g fat); and those Ͼ250 lb (114 kg) were instructed to follow a 2000-kcal/day diet (55 g fat).
Pharmacological interventions
Three diabetes prevention trials used pharmacological therapy, and all have reported a significant lowering of the incidence of diabetes. The biguanide metformin reduced the risk of diabetes by 31% in the DPP (13), the ␣-glucosidase inhibitor acarbose reduced the risk by 32% in the STOP-NIDDM trial (15) , and the thiazolidinedione troglitazone reduced the risk by 56% in the TRIPOD study (14) .
In the DPP, metformin was about half as effective as diet and exercise in delaying the onset of diabetes overall, but it was nearly ineffective in older individuals (Ն60 years of age) or in those who were less overweight (BMI Ͻ30 kg/m 2 ). Conversely, metformin was as effective as lifestyle modification in individuals aged 24 -44 years or in those with a BMI Ն35 kg/m 2 . Thus, the population of people in whom treatment with metformin has equal benefit to that of a lifestyle intervention is only a small subset of those who are likely to have pre-diabetes (IFG or IGT).
There are also data to suggest that blockade of the rennin-angiotensin system (17) may lower the risk of developing diabetes, but more studies are necessary before these drugs can be recommended for preventing diabetes.
Lifestyle or medication?
The DPP is the only study in which a comparison of the two was made, and lifestyle modification was nearly twice as effective in preventing diabetes (58 vs. 31% relative reductions, respectively). The greater benefit of weight loss and physical activity strongly suggests that lifestyle modification should be the first choice to prevent or delay diabetes. Modest weight loss (5-10% of body weight) and modest physical activity (30 min daily) are the recommended goals. Because this intervention not only has been shown to prevent or delay diabetes, but also has a variety of other benefits, health care providers should urge all overweight or sedentary individuals to adopt these changes, and such recommendations should be made at every opportunity.
When all factors are considered, there is insufficient evidence to support the use of drug therapy as a substitute for, or routinely used in addition to, lifestyle modification to prevent diabetes. Public health messages, health care professionals, and health care systems should all encourage behavior changes to achieve a healthy lifestyle. Further research is necessary to understand better how to facilitate effective and efficient programs for the primary prevention of type 2 diabetes. 
Recommendations
V. DIABETES CARE
A. Initial evaluation A complete medical evaluation should be performed to classify the patient, detect the presence or absence of diabetes complications, assist in formulating a management plan, and provide a basis for continuing care. If the diagnosis of diabetes has already been made, the evaluation should review the previous treatment and the past and present degrees of glycemic control. Laboratory tests appropriate to the evaluation of each patient's general medical condition should be performed. A focus on the components of comprehensive care (Table 5) will assist the health care team to ensure optimal management of the patient with diabetes.
B. Management
People with diabetes should receive medical care from a physician-coordinated team. Such teams may include, but are not limited to, physicians, nurse practitioners, physician's assistants, nurses, dietitians, pharmacists, and mental health professionals with expertise and a special interest in diabetes. It is essential in this collaborative and integrated team approach that individuals with diabetes assume an active role in their care. The management plan should be formulated as an individualized therapeutic alliance among the patient and family, the physician, and other members of the health care team. Any plan should recognize diabetes self-management education (DSME) as an integral component of care.
In developing the plan, consideration should be given to the patient's age, school or work schedule and conditions, physical activity, eating patterns, social situation and personality, cultural factors, (18, 19) . Major clinical trials assessing the impact of glycemic control on diabetes complications have included SMBG as part of multifactorial interventions, suggesting that SMBG is a component of effective therapy. SMBG allows patients to evaluate their individual response to therapy and assess whether glycemic targets are being achieved. Results of SMBG can be useful in preventing hypoglycemia and adjusting medications, medical nutrition therapy (MNT), and physical activity.
The frequency and timing of SMBG should be dictated by the particular needs and goals of the patients. Daily SMBG is especially important for patients treated with insulin to monitor for and prevent asymptomatic hypoglycemia and hyperglycemia. For most patients with type 1 diabetes and pregnant women taking insulin, SMBG is recommended three or more times daily. The optimal frequency and timing of SMBG for patients with type 2 diabetes on oral agent therapy is not known but should be sufficient to facilitate reaching glucose goals. Patients with type 2 diabetes on insulin typically need to perform SMBG more frequently than those not using insulin. When adding to or modifying therapy, type 1 and type 2 diabetic patients should test more often than usual. The role of SMBG in stable diet-treated patients with type 2 diabetes is not known.
Because the accuracy of SMBG is instrument-and user-dependent (20) , it is important for health care providers to evaluate each patient's monitoring technique, both initially and at regular intervals thereafter. In addition, optimal use of SMBG requires proper interpretation of the data. Patients should be taught how to use the data to adjust food intake, exercise, or pharmacological therapy to achieve specific glycemic goals. Health professionals should evaluate at regular intervals the patient's ability to use SMBG data to guide treatment. (20) and, thus, assess treatment efficacy. A1C testing should be performed routinely in all patients with diabetes, first to document the degree of glycemic control at initial assessment and then as part of continuing care. Since the A1C test reflects mean glycemia over the preceding 2-3 months, measurement approximately every 3 months is required to determine whether a patient's metabolic control has been reached and maintained within the target range. Thus, regular performance of the A1C test permits detection of departures from the target (Table  6 ) in a timely fashion. For any individual patient, the frequency of A1C testing goals are not met despite reaching preprandial glucose goals *Referenced to a nondiabetic range of 4.0 -6.0% using a DCCT-based assay. †Postprandial glucose measurements should be made 1-2 h after the beginning of the meal, generally peak levels in patients with diabetes. ‡Current NCEP/ATP III guidelines suggest that in patients with triglycerides Ն200 mg/dl, the "non-HDL cholesterol" (total cholesterol minus HDL) be used. The goal is Յ130 mg/dl (31). §For women, it has been suggested that the HDL goal be increased by 10 mg/dl.
Recommendations
should be dependent on the clinical situation, the treatment regimen used, and the judgment of the clinician. Glycemic control is best judged by the combination of the results of the patient's SMBG testing (as performed) and the current A1C result. The A1C should be used not only to assess the patient's control over the preceding 2-3 months but also as a check on the accuracy of the meter (or the patient's self-reported results) and the adequacy of the SMBG testing schedule. • Attain and maintain recommended metabolic outcomes, including glucose and A1C levels, LDL cholesterol, HDL cholesterol, triglyceride levels, blood pressure, and body weight (Table 6 ). 
Goals of MNT that apply to specific situations include the following:
• For youth with type 1 diabetes (34), provide adequate energy to ensure normal growth and development; integrate insulin regimens into usual eating and physical activity habits.
• For youth with type 2 diabetes, who are often overweight/obese, facilitate appropriate changes in eating and physical activity habits.
• For pregnant and lactating women, provide adequate energy and nutrients needed for optimal outcomes. In pregnancy, counting and recording carbohydrate intake contributes to optimal glycemic control.
• For older adults, provide for the nutritional and psychosocial needs of an aging individual.
• For individuals treated with insulin or insulin secretagogues, provide selfmanagement education for treatment (and prevention) of hypoglycemia, acute illnesses, and exercise-related blood glucose problems.
• For individuals at risk for diabetes, decrease risk by encouraging physical activity and promoting foods choices that facilitate moderate weight loss or at least prevent weight gain.
Achieving nutrition-related goals requires a coordinated team effort that includes the person with diabetes. Because of the complexity of nutrition issues, it is recommended that a registered dietitian, knowledgeable and skilled in implementing nutrition therapy into diabetes management and education, is the team member who provides MNT. However, it is essential that all team members are knowledgeable about nutrition therapy and are supportive of the person with diabetes who needs to make lifestyle changes.
MNT involves a nutrition assessment to evaluate the patient's food intake, metabolic status, lifestyle and readiness to make changes, goal setting, dietary instruction, and evaluation. To facilitate adherence, the plan should be individualized and take into account cultural, lifestyle, and financial considerations. Monitoring of glucose and A1C, lipids, blood pressure, and renal status is essential to evaluate nutrition-related outcomes. If goals are not met (Table 6) , changes must be made in the overall diabetes care and management plan. Dietary carbohydrate (35) . Regulation of blood glucose to achieve near normal levels is a primary goal in the management of diabetes, and thus, dietary techniques that limit hyperglycemia following a meal are important in limiting the complications of diabetes. Both the amount (grams) of carbohydrate as well as the type of carbohydrate in a food influence blood glucose level. The total amount of carbohydrate consumed is a strong predictor of glycemic response, and thus, monitoring total grams of carbohydrate, whether by use of exchanges or carbohydrate counting, remains a key strategy in achieving glycemic control. A recent analysis of the randomized, controlled trials that have examined the efficacy of the glycemic index (a measure of the effect of type of carbohydrate) on overall blood glucose control indicates that the use of this technique can provide an additional benefit over that observed when total carbohydrate is considered alone.
Low carbohydrate diets are not recommended in the management of diabetes. Although dietary carbohydrate is the major contributor to postprandial glucose concentration, it is an important source of energy, water soluble vitamins and minerals, and fiber. Thus, in agreement with the National Academy of Sciences-Food and Nutrition Board, a recommended range of carbohydrate intake is 45-65% of total calories. In addition, because the brain and central nervous system have an absolute requirement for glucose as an energy source, restricting total carbohydrate to Ͻ130 g/day is not recommended. Weight management (36) . Overweight and obesity are strongly linked to the development of type 2 diabetes and can complicate its management. Obesity is also an independent risk factor for hypertension and dyslipidemia as well as CVD, which is the major cause of death in those with diabetes. Moderate weight loss improves glycemic control, reduces CVD risk, and can prevent the development of type 2 diabetes in those with pre-diabetes. Therefore, weight loss is an important therapeutic strategy in all overweight or obese individuals who have type 2 diabetes or are at risk for developing diabetes. The primary approach for achieving weight loss, in the vast majority of cases, is therapeutic lifestyle change, which includes a reduction in energy intake and an increase in physical activity. A moderate decrease in caloric balance (500 -1,000 kcal/day) will result in a slow but progressive weight loss (1-2 lb/week). For most patients, weight loss diets should supply at least 1,000 -1,200 kcal/day for women and 1,200 -1,600 kcal/day for men.
Physical activity is an important component of a comprehensive weight management program. Regular, moderate intensity, physical activity enhances longterm weight maintenance. Regular activity also improves insulin sensitivity, glycemic control, and selected risk factors for CVD (i.e., hypertension and dyslipidemia), and increased aerobic fitness decreases the risk of coronary heart disease (CHD). Initial physical activity recommendations should be modest, based on the patient's willingness and ability, gradually increasing the duration and frequency to 30 -45 min of moderate aerobic activity 3-5 days per week, when possible. Greater activity levels of at least 1 h/day of moderate (walking) or 30 min/ day of vigorous (jogging) activity may be needed to achieve successful long-term weight loss. E. Physical activity ADA technical reviews on exercise in patients with diabetes have summarized the value of exercise in the diabetes management plan (37, 38) . Regular exercise has been shown to improve blood glucose control, reduce cardiovascular risk factors, contribute to weight loss, and improve well-being. Furthermore, regular exercise may prevent type 2 diabetes in high-risk individuals (12, 13, 16) . Before beginning a physical activity program, the patient with diabetes should have a detailed medical evaluation with appropriate diagnostic studies. This examination should screen for the presence of macro-and microvascular complications that may be worsened by the physical activity program (see next section regarding CHD screening). Identification of areas of concern will allow the design of an individualized physical activity plan that can minimize risk to the patient.
Recommendations
All levels of physical activity, including leisure activities, recreational sports, and competitive professional performance, can be performed by people with diabetes who do not have complications and have good glycemic control. The ability to adjust the therapeutic regimen (insulin therapy and MNT) to allow safe participation is an important management strategy.
• A regular physical activity program, adapted to the presence of complications, is recommended for all patients with diabetes who are capable of participating. (B)
F. Psychosocial assessment and care Psychological and social state can impact the patient's ability to carry out diabetes care tasks (39 -44) . As a result, health status may be compromised. Family conflict around diabetes care tasks is also common and may interfere with treatment outcomes (45) . There are opportunities for the clinician to assess psychosocial status in a timely and efficient manner so that referral for appropriate services can be accomplished (46) . Key opportunities for screening of psychosocial status occur at diagnosis, during regularly scheduled management visits, during hospitalizations, at discovery of complications, or at the discretion of the clinician when problems in glucose control, quality of life, or adherence are identified (47) . Patients are likely to exhibit psychological vulnerability at diagnosis and when their medical status changes: the end of the honeymoon period, when the need for intensified treatment is evident and when complications are discovered (42, 44) .
Psychosocial screening should include but is not limited to: attitudes about the illness, expectations for medical management and outcomes, affect/mood, general and diabetes related quality of life, resources (financial, social, and emotional), (43) and psychiatric history (44, 47, 48) . Particular attention needs to be paid to gross noncompliance with medical regimen (due to self or others) (39, 48) , depression with the possibility of self-harm (40, 41) , indications of an eating disorder (49) or a problem that appears to be organic in origin, and cognitive functioning that significantly impairs judgment (41) . In these cases, immediate referral for further evaluation by a mental health specialist familiar with diabetes management should occur. Behavioral assessment of management skills is also recommended.
It is preferable to incorporate psychological treatment into routine care rather than waiting for identification of a specific problem or deterioration in psychological status (46) . Screening tools can facilitate this goal, and although the clinician may not feel qualified to treat psychological problems, utilizing the patient-provider relationship as a foundation for further treatment can increase the likelihood that the patient will accept referral for other services. It is important to establish that emotional wellbeing is part of diabetes management (47) . 
G. Referral for diabetes management
For a variety of reasons, some people with diabetes and their health care providers do not achieve the desired goals of treatment (Table 6 ). Intensification of the treatment regimen is suggested and includes identification (or assessment) of barriers to adherence, culturally appropriate and enhanced DSME, comanagement with a diabetes team, change in pharmacological therapy, initiation of or increase in SMBG, more frequent contact with the patient, and referral to an endocrinologist.
H. Intercurrent illness
The stress of illness, trauma, and/or surgery frequently aggravates glycemic control and may precipitate diabetic ketoacidosis (DKA) or nonketotic hyperosmolar state. Any condition leading to deterioration in glycemic control necessitates more frequent monitoring of blood (51) .
Aggressive glycemic management with insulin may reduce morbidity in patients with severe acute illness (52) . For information on management of patients in the hospital with DKA or nonketotic hyperosmolar state, refer to the ADA position statement titled "Hyperglycemic Crises in Diabetes" (50) .
I. Immunization
Influenza and pneumonia are common, preventable infectious diseases associated with high mortality and morbidity in the elderly and in people with chronic diseases. There are limited studies reporting the morbidity and mortality of influenza and pneumococcal pneumonia, specifically in people with diabetes. Observational studies of patients with a variety of chronic illnesses, including diabetes, show that these conditions are associated with an increase in hospitalizations for influenza and its complications. Based on a case-control series, influenza vaccine has been shown to reduce diabetes-related hospital admission by as much as 79% during flu epidemics (53) . People with diabetes may be at increased risk of the bacteremic form of pneumococcal infection and have been reported to have a high risk of nosocomial bacteremia, which has a mortality rate as high as 50%.
Safe and effective vaccines are available that can greatly reduce the risk of serious complications from these diseases (54, 55 
VI. PREVENTION AND MANAGEMENT OF DIABETES COMPLICATIONS
A. CVD CVD is the major cause of mortality for individuals with diabetes. It is also a major contributor to morbidity and direct and indirect costs of diabetes. Type 2 diabetes is an independent risk factor for macrovascular disease, and its common coexisting conditions (e.g., hypertension and dyslipidemia) are also risk factors. Studies have shown the efficacy of reducing cardiovascular risk factors in preventing or slowing CVD. Evidence is summarized in the following sections and reviewed in detail in the ADA technical reviews on hypertension (58), dyslipidemia (59), aspirin therapy (60), and smoking cessation (61) and the consensus statement on CHD in people with diabetes (62) . Emphasis should be placed on reducing cardiovascular risk factors, when possible, and clinicians should be alert for signs and symptoms of atherosclerosis.
1. Hypertension/blood pressure control. Hypertension (HTN) (blood pressure Ն140/90 mmHg) is a common comorbidity of diabetes, affecting the majority of people with diabetes, depending on type of diabetes, age, obesity, and ethnicity. HTN is also a major risk factor for CVD and microvascular complications such as retinopathy and nephropathy. In type 1 diabetes, HTN is often the result of underlying nephropathy. In type 2 diabetes, HTN may be present as part of the metabolic syndrome (i.e., obesity, hyperglycemia, and dyslipidemia) that is accompanied by high rates of CVD.
Randomized clinical trials have demonstrated the benefit (reduction of CHD events, stroke, and nephropathy) of lowering blood pressure to Ͻ130 mmHg systolic and Ͻ80 mmHg diastolic in individuals with diabetes (63) (64) (65) (66) . Epidemiologic analyses show that blood pressure Ͼ115/75 mmHg is associated with increased cardiovascular event rates and mortality in individuals with diabetes (63, 67, 68) . Therefore, a target blood pressure goal of Ͻ130/80 mmHg is reasonable if it can be safely achieved.
Although there are no well-controlled studies of diet and exercise in the treatment of HTN in individuals with diabetes, reducing sodium intake and body weight (when indicated); increasing consumption of fruits, vegetables, and low-fat dairy products; avoiding excessive alcohol consumption; and increasing activity levels have been shown to be effective in reducing blood pressure in nondiabetic individuals (69) . These nonpharmacological strategies may also positively affect glycemia and lipid control. Their effects on cardiovascular events have not been well measured.
Lowering of blood pressure with regimens based on antihypertensive drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), ␤-blockers, diuretics, and calcium channel blockers, has been shown to be effective in lowering cardiovascular events. Several studies suggest that ACE inhibitors may be superior to dihydropyridine calcium channel blockers (DCCBs) in reducing cardiovascular events (70, 71) . Additionally, in people with diabetic nephropathy indicate that ARBs may be superior to DCCBs for reducing cardiovascular events (72) . Conversely, in the recently completed International Verapamil Study (INVEST) of Ͼ22,000 people with coronary artery dis-ease (CAD) and hypertension, the non-DCCB, verapamil, demonstrated a similar reduction in cardiovascular mortality to a ␤-blocker. Moreover, this relationship held true in the diabetic subgroup (73) .
ACE inhibitors have been shown to improve cardiovascular outcomes in high-cardiovascular-risk patients with or without HTN (74, 75) . In patients with congestive heart failure (CHF), ACE inhibitors are associated with better outcomes when compared with ARBs. In one study an ARB was superior to a ␤-blocker as a therapy to improve cardiovascular outcomes in a subset of diabetic patients with HTN and left ventricular hypertrophy (76) . The compelling effect of ACE inhibitors or ARBs in patients with albuminuria or renal insufficiency provide additional rationale for use of these agents (see section VI B. below).
The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), a large randomized trial of different initial blood pressure pharmacological therapies, found no large differences between initial therapy with a chlorthalidone, amlodipine, and lisinopril. Diuretics appeared slightly more effective than other agents, particularly for reducing heart failure (77). The ␣-blocker arm of the ALLHAT was terminated after interim analysis showed that doxazosin was substantially less effective in reducing CHF than diuretic therapy (78) .
Before beginning treatment, patients with elevated blood pressures should have their blood pressure reexamined within 1 month to confirm the presence of HTN. Systolic blood pressure Ն160 mmHg or diastolic blood pressure Ն100 mmHg, however, mandates that immediate pharmacological therapy be initiated. Patients with HTN should be seen as often as needed until the recommended blood pressure goal is obtained and then seen as necessary (63) . In these patients, other cardiovascular risk factors, including obesity, hyperlipidemia, smoking, presence of microalbuminuria (assessed before initiation of treatment), and glycemic control, should be carefully assessed and treated. Many patients will require three or more drugs to reach target goals.
During pregnancy in diabetic women with chronic HTN, target blood pressure goals of systolic blood pressure 110 -129 mmHg and diastolic blood pressure 65-79 mmHg are reasonable as they may contribute to long-term maternal health. Lower blood pressure levels may be associated with impaired fetal growth. During pregnancy treatment with ACE inhibitors and ARBs is contraindicated, since they are likely to cause fetal damage. Antihypertensive drugs known to be effective and safe in pregnancy include methyldopa, labetalol, diltiazem, clonidine, and prazosin. Chronic diuretic use during pregnancy has been associated with restricted maternal plasma volume, which might reduce uteroplacental perfusion. (79 -82) . In two studies using the fibric acid derivative gemfibrozil, reductions in cardiovascular end points were also achieved (83, 84) . Target lipid levels are shown in Table  6 . Lifestyle intervention including MNT, increased physical activity, weight loss, and smoking cessation should allow some patients to reach these lipid levels. Nutrition intervention should be tailored according to each patient's age, type of diabetes, pharmacological treatment, lipid levels, and other medical conditions and should focus on the reduction of saturated fat, cholesterol, and transunsaturated fat intake. Glycemic control can also beneficially modify plasma lipid levels. Particularly in patients with very high triglycerides and poor glycemic control, glucose lowering maybe necessary to control hypertriglyceridemia. Pharmacological treatment is indicated if there is an inadequate response to lifestyle modifications and improved glucose control. However, in patients with clinical CVD and LDL Ͼ100 mg/dl, pharmacological therapy should be initiated at the same time that lifestyle intervention is started. In patients with diabetes aged Ͻ40 years similar consideration for LDL lowering therapy should be given if they have increased cardiovascular risk (e.g., additional cardiovascular risk factors or long duration of diabetes). Very little clinical trial data exists in patients in this agegroup.
Recommendations
Screening and diagnosis
The first priority of pharmacological therapy is to lower LDL cholesterol to a target goal of Ͻ100 mg/dl (2.60 mmol/l) or therapy to achieve a reduction in LDL of 30 -40%. For LDL lowering, statins are the drugs of choice. Other drugs that lower LDL include nicotinic acid, ezetimbe, bile acid sequestrants, and fenofibrate (31,85).
The Heart Protection Study (82) demonstrated that in people with diabetes over the age of 40 years with a total cholesterol Ͼ135 mg/dl, LDL reduction of ϳ30% from baseline with the statin simvastatin was associated with an ϳ25% reduction in the first event rate for major coronary artery events independent of baseline LDL, preexisting vascular disease, type or duration of diabetes, or adequacy of glycemic control. Similarly in the Collaborative Atorvastatin Diabetes Study (CARDS) study (86) , patients with type 2 diabetes randomized to atorvastatin 10 mg daily had a significant reduction in cardiovascular events including stroke.
Recent clinical trials in high-risk patients, such as those with acute coronary syndromes or previous cardiovascular events ( [87] [88] [89] , have demonstrated that more aggressive therapy with high doses of statins to achieve an LDL of Ͻ70 mg/dl led to a significant reduction in further events. The risk of side effects with high doses of statins is significantly outweighed by the benefits of such therapy in these high-risk patients. Therefore a reduction in LDL to a goal of Ͻ70 mg/dl is an option in very-high-risk patients with overt CVD (85) .
Relatively little data are available on lipid lowering therapy in subjects with type 1 diabetes. In the Heart Protection Study ϳ600 patients with type 1 diabetes had a proportionately similar, but not statistically significant, reduction in risk as in the patients with type 2 diabetes. Although the data are not definitive, consideration should be given to similar lipidlowering therapy in patients with type 1 diabetes as in type 2 diabetes, particularly if they have other cardiovascular risk factors or features of the metabolic syndrome.
If the HDL is Ͻ40 mg/dl and the LDL is between 100 and 129 mg/dl, a fibric acid derivative or niacin might be used. Niacin is the most effective drug for raising HDL but can significantly increase blood glucose at high doses. More recent studies demonstrate that at modest doses (750 -2,000 mg/day), significant benefit with regards to LDL, HDL, and triglyceride levels are accompanied by only modest changes in glucose that are generally amenable to adjustment of diabetes therapy (90, 91) .
Combination therapy, with a statin and a fibrate or statin and niacin, may be efficacious for patients needing treatment for all three lipid fractions, but this combination is associated with an increased risk for abnormal transaminase levels, myositis, or rhabdomyolysis. The risk of rhabdomyolysis seems to be lower when statins are combined with fenofibrate than gemfibrozil. There is also a risk of a rise in plasma creatinine, particularly with fenofibrate. It is important to note that clinical trials with fibrates and niacin have demonstrated benefits in patients who were not on treatment with statins and that there is no data available on reduction of events with such combinations. The risks may be greater in patients who are treated with combinations of these drugs with high doses of statins. Dosages used in most clinical trials ranged from 75 to 325 mg/day. There is no evidence to support any specific dose, but using the lowest possible dosage may help reduce side effects. There is no evidence for a specific age at which to start aspirin, but at ages Ͻ30 years, aspirin has not been studied.
Recommendations
Screening
Clopidogrel has been demonstrated to reduce CVD rates in diabetic individuals (95) . Adjunctive therapy in very highrisk patients or as alternative therapy in aspirin-intolerant patients should be considered. A number of large randomized clinical trials have demonstrated the efficacy and cost-effectiveness of counseling in changing smoking behavior. Such studies, combined with others specific to individuals with diabetes, suggest that smoking cessation counseling is effective in reducing tobacco use (97, 98) .
Recommendations
The routine and thorough assessment of tobacco use is important as a means of preventing smoking or encouraging cessation. Special considerations should include assessment of level of nicotine dependence, which is associated with difficulty in quitting and relapse. 5. CHD screening and treatment. CHD screening and treatment are reviewed in detail in the ADA consensus statement on CHD in people with diabetes (62) . To identify the presence of CHD in diabetic patients without clear or suggestive symptoms of CAD, a risk factor-based approach to the initial diagnostic evaluation and subsequent follow-up is recommended. A recent study concluded that using current guidelines fails to detect a significant percentage of patients with silent ischemia (99) . At least annually, cardiovascular risk factors should be assessed. These risk factors include dyslipidemia, hypertension, smoking, a positive family history of premature coronary disease, and the presence of micro-or macroalbuminuria. Abnormal risk factors should be treated as described elsewhere in these guidelines.
Patients at increased CHD risk should receive aspirin and may warrant an ACE inhibitor.
Candidates for a diagnostic cardiac stress test include those with 1) typical or atypical cardiac symptoms and 2) an abnormal resting electrocardiogram (ECG). Candidates for a screening cardiac stress test include those with 1) a history of peripheral or carotid occlusive disease; 2) sedentary lifestyle, age Ͼ35 years, and plans to begin a vigorous exercise program; and 3) two or more of the risk factors noted above.
Current evidence suggests that noninvasive tests can improve assessment of future CHD risk. There is, however, no current evidence that such testing in asymptomatic patients with risk factors improves outcomes or leads to better utilization of treatments (100).
Patients with abnormal exercise ECG and patients unable to perform an exercise ECG require additional or alternative testing. Currently, stress nuclear perfusion and stress echocardiography are valuable next-level diagnostic procedures. A consultation with a cardiolo-gist is recommended regarding further work-up. (101, 102) . Patients with microalbuminuria who progress to macroalbuminuria (Ն300 mg/24 h) are likely to progress to ESRD over a period of years (103, 104) . Over the past several years, a number of interventions have been demonstrated to reduce the risk and slow the progression of renal disease.
Intensive diabetes management with the goal of achieving near normoglycemia has been shown in large prospective randomized studies to delay the onset of microalbuminuria and the progression of micro-to macroalbuminuria in patients with type 1 (105,106) and type 2 diabetes (23,24). The UKPDS provided strong evidence that control of blood pressure can reduce the development of nephropathy (64) . In addition, large prospective randomized studies in patients with type 1 diabetes have demonstrated that achievement of lower levels of systolic blood pressure (Ͻ140 mmHg) achieved with treatment using ACE inhibitors provides a selective benefit over other antihypertensive drug classes in delaying the progression from micro-to macroalbuminuria and can slow the decline in glomerular filtration rate (GFR) in patients with macroalbuminuria (64, (107) (108) (109) .
In addition, ACE inhibitors have been shown to reduce severe CVD (i.e., myocardial infarction, stroke, and death), thus further supporting the use of these agents in patients with microalbuminuria (74). ARBs have also been shown to reduce the rate of progression from micro-to macroalbuminuria as well as ESRD in patients with type 2 diabetes (110 -112) . Some evidence suggests that ARBs have a smaller magnitude of rise in potassium compared with ACE inhibitors in people with nephropathy (73) . With regard to slowing the progression of nephropathy, the use of DCCBs as initial therapy is not more effective than placebo. Their use in nephropathy should be restricted to additional therapy to further lower blood pressure in patients already treated with ACE inhibitors or ARBs (72) . In the setting of albuminuria or nephropathy, in patients unable to tolerate ACE inhibitors and/or ARBs, consider the use of nonDCCBs, ␤-blockers, or diuretics for the management of blood pressure (73, 113) .
A meta-analysis of several small studies has shown that protein restriction may be of benefit in some patients whose nephropathy seems to be progressing despite optimal glucose and blood pressure control (114) .
Screening for microalbuminuria can be performed by three methods: 1) measurement of the albumin-to-creatinine ratio in a random, spot collection (preferred method); 2) 24-h collection with creatinine, allowing the simultaneous measurement of creatinine clearance; and 3) timed (e.g., 4-h or overnight) collection.
The analysis of a spot sample for the albumin-to-creatinine ratio is strongly recommended by most authorities (115, 116) . The other two alternatives (24-h collection and a timed specimen) are rarely necessary. Measurement of a spot urine for albumin only, whether by immunoassay or by using a dipstick test specific for microalbumin, without simultaneously measuring urine creatinine is less expensive than the recommended methods but is susceptible to falsenegative and false-positive determinations as a result of variation in urine concentration due to hydration and other factors.
At least two of three tests measured within a 6-month period should show elevated levels before a patient is designated as having microalbuminuria. Abnormalities of albumin excretion are defined in Table 8 .
Screening for microalbuminuria is indicated in pregnancies complicated by diabetes, since microalbuminuria in the absence of urinary tract infection is a strong predictor of superimposed preeclampsia. In the presence of macroalbuminuria or urine dipstick proteinuria, estimation of GFR by serum creatinine or 24-h urine creatinine clearance is indicated to stage the patient's renal disease, and other tests may be necessary to diagnose preeclampsia.
Physicians may use the Levey modification of the Cockcroft and Gault equation to calculate estimated GFR (eGFR) from serum creatinine and to stage the patient's re- Because of variability in urinary albumin excretion, two of three specimens collected within a 3-to 6-month period should be abnormal before considering a patient to have crossed one of these diagnostic thresholds. Exercise within 24 h, infection, fever, CHF, marked hyperglycemia, and marked hypertension may elevate urinary albumin excretion over baseline values.
nal disease (117) . The eGFR can easily be calculated by accessing http://www.kidney. org/kls/professionals/gfr_calculator.cfm. The role of annual microalbumuria assessment is less clear after diagnosis of microalbuminuria and institution of ACE inhibitor or ARB therapy and blood pressure control. Most experts, however, recommend continued surveillance to assess both response to therapy and progression of disease. Some experts suggest that reducing urine microalbuminuria to the normal or near-normal range, if possible, may improve renal and cardiovascular prognosis. This approach has not been formally evaluated in prospective trials.
Consider referral to a physician experienced in the care of diabetic renal disease either when the GFR has fallen to Ͻ60 ml ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 or if difficulties occur in the management of hypertension or hyperkalemia. It is suggested that consultation with a nephrologist be obtained when the GFR is Ͻ30 ml ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 . Early referral of such patients has been found to reduce cost and improve quality of care and keep people off dialysis longer (118) . For a complete discussion on the treatment of nephropathy, see the ADA position statement "Diabetic Nephropathy" (119) C. Retinopathy screening and treatment Diabetic retinopathy is a highly specific vascular complication of both type 1 and type 2 diabetes. The prevalence of retinopathy is strongly related to the duration of diabetes. Diabetic retinopathy is estimated to be the most frequent cause of new cases of blindness among adults aged 20 -74 years.
General recommendations
Intensive diabetes management with the goal of achieving near normoglycemia has been shown in large prospective randomized studies to prevent and/or delay the onset of diabetic retinopathy (22) (23) (24) . In addition to glycemic control, several other factors seem to increase the risk of retinopathy. The presence of nephropathy is associated with retinopathy. High blood pressure is an established risk factor for the development of macular edema and is associated with the presence of proliferative diabetic retinopathy (PDR). Lowering blood pressure, as demonstrated by the UKPDS, has been shown to decrease the progression of retinopathy. Several case series and a controlled prospective study suggest that pregnancy in type 1 diabetic patients may aggravate retinopathy (119a). During pregnancy and 1-year postpartum, retinopathy may be transiently aggravated; laser photocoagulation surgery can minimize this risk (120).
Patients with type 1 diabetes should have an initial dilated and comprehensive eye examination by an ophthalmologist or optometrist within 5 years after the onset of diabetes. Patients with type 2 diabetes should have an initial dilated and comprehensive eye examination by an ophthalmologist or optometrist shortly after the diagnosis of diabetes. Subsequent examinations for type 1 and type 2 diabetic patients should be repeated annually by an ophthalmologist or optometrist who is knowledgeable and experienced in diagnosing the presence of diabetic retinopathy and is aware of its management. Less frequent exams (every 2-3 years) may be considered with the advice of an eye care professional in the setting of a normal eye exam (121) (122) (123) . Examinations will be required more frequently if retinopathy is progressing.
One of the main motivations for screening for diabetic retinopathy is the established efficacy of laser photocoagulation surgery in preventing visual loss. Two large National Institutes of Healthsponsored trials, the Diabetic Retinopathy Study (DRS) and the Early Treatment Diabetic Retinopathy Study (ETDRS), provide the strongest support for the therapeutic benefit of photocoagulation surgery
The DRS tested whether scatter (panretinal) photocoagulation surgery could reduce the risk of vision loss from PDR. Severe visual loss (i.e., best acuity of 5/200 or worse) was seen in 15.9% of un-treated versus 6.4% of treated eyes. The benefit was greatest among patients whose baseline evaluation revealed highrisk characteristics (HRCs) (chiefly disc neovascularization or vitreous hemorrhage with any retinal neovascularization). Of control eyes with HRCs, 26% progressed to severe visual loss versus 11% of treated eyes. Given the risk of a modest loss of visual acuity and of contraction of visual field from panretinal laser surgery, such therapy has been primarily recommended for eyes approaching or reaching HRCs.
The ETDRS established the benefit of focal laser photocoagulation surgery in eyes with macular edema, particularly those with clinically significant macular edema. In patients with clinically significant macular edema after 2 years, 20% of untreated eyes had a doubling of the visual angle (e.g., 20/50 to 20/100) compared with 8% of treated eyes. Other results from the ETDRS indicate that, provided careful follow-up can be maintained, scatter photocoagulation surgery is not recommended for eyes with mild or moderate non-PDR (NPDR). When retinopathy is more severe, scatter photocoagulation surgery should be considered, and usually should not be delayed, if the eye has reached the high-risk proliferative stage. In older-onset patients with severe NPDR or less than high-risk PDR, the risk of severe visual loss and vitrectomy is reduced ϳ50% by laser photocoagulation surgery at these earlier stages.
Laser photocoagulation surgery in both the DRS and the ETDRS was beneficial in reducing the risk of further visual loss but generally not beneficial in reversing already diminished acuity. This preventive effect and the fact that patients with PDR or macular edema may be asymptomatic provide strong support for a screening program to detect diabetic retinopathy.
For a detailed review of the evidence and further discussion, see the ADA technical review and position statement on this subject (119a,124,125) . • Peripheral neuropathy with loss of protective sensation.
Recommendations
General recommendations
• Altered biomechanics (in the presence of neuropathy).
• Evidence of increased pressure (erythema, hemorrhage under a callus).
• Bony deformity.
• Peripheral vascular disease (decreased or absent pedal pulses).
• A history of ulcers or amputation.
• Severe nail pathology.
All individuals with diabetes should receive an annual foot examination to identify high-risk foot conditions. This examination should include assessment of protective sensation, foot structure and biomechanics, vascular status, and skin integrity. People with one or more highrisk foot conditions should be evaluated more frequently for the development of additional risk factors. People with neuropathy should have a visual inspection of their feet at every visit with a health care professional. Evaluation of neurological status in the low-risk foot should include a quantitative somatosensory threshold test, using the Semmes-Weinstein 5.07 (10 g) monofilament. The skin should be assessed for integrity, especially between the toes and under the metatarsal heads. The presence of erythema, warmth, or callus formation may indicate areas of tissue damage with impending breakdown. Bony deformities, limitation in joint mobility, and problems with gait and balance should be assessed.
People with neuropathy or evidence of increased plantar pressure may be adequately managed with well-fitted walking shoes or athletic shoes. Patients should be educated on the implications of sensory loss and the ways to substitute other sensory modalities (hand palpation, visual inspection) for surveillance of early problems. People with evidence of increased plantar pressure (e.g., erythema, warmth, callus, or measured pressure) should use footwear that cushions and re-distributes the pressure. Callus can be debrided with a scalpel by a foot care specialist or other health professional with experience and training in foot care. People with bony deformities (e.g., hammertoes, prominent metatarsal heads, and bunions) may need extra-wide shoes or depth shoes. People with extreme bony deformities (e.g., Charcot foot) that cannot be accommodated with commercial therapeutic footwear may need custommolded shoes.
Initial screening for peripheral arterial disease (PAD) should include a history for claudication and an assessment of the pedal pulses. Consider obtaining an ankle-brachial index (ABI), as many patients with PAD are asymptomatic. Refer patients with significant or a positive ABI for further vascular assessment and consider exercise, medications, and surgical options (126) .
Patients with diabetes and high-risk foot conditions should be educated regarding their risk factors and appropriate management. Patients at risk should understand the implications of the loss of protective sensation, the importance of foot monitoring on a daily basis, the proper care of the foot, including nail and skin care, and the selection of appropriate footwear. The patient's understanding of these issues and their physical ability to conduct proper foot surveillance and care should be assessed. Patients with visual difficulties, physical constraints preventing movement, or cognitive problems that impair their ability to assess the condition of the foot and to institute appropriate responses will need other people, such as family members, to assist in their care. Patients at low risk may benefit from education on foot care and footwear.
For a detailed review of the evidence and further discussion, see the ADA technical review and position statement in this area (127, 128) .
Problems involving the feet, especially ulcers and wound care, may require care by a podiatrist, orthopedic surgeon, or rehabilitation specialist experienced in the management of individuals with diabetes. For a complete discussion on wound care, see the ADA consensus statement on diabetic foot wound care (129) . (34) . The following represents a summary of recommendations and guidelines pertaining specifically to the care and management of children and adolescents that are included in that document. Ideally, the care of a child or adolescent with type 1 diabetes should be provided by a multidisciplinary team of specialists trained in the care of children with pediatric diabetes, although this may not always be possible. At the very least, education of the child and family should be provided by health care providers trained and experienced in childhood diabetes and sensitive to the challenges posed by diabetes in this age-group. At the time of initial diagnosis, it is essential that diabetes education be provided in a timely fashion, with the expectation that the balance between adult supervision and self-care should be defined by and will evolve according to physical, psychologic, and emotional maturity. MNT should be provided at diagnosis, and at least annually thereafter, by an individual experienced with the nutritional needs of the growing child and the behavioral issues that have an impact on adolescent diets.
a. Glycemic control. While current standards for diabetes management reflect the need to maintain glucose control as near to normal as safely possible, special consideration must be given to the unique risks of hypoglycemia in young children. Glycemic goals need to be modified to take into account the fact that most children younger than 6 or 7 years of age have a form of "hypoglycemic unawareness," in that counterregulatory mechanisms are immature, and young children lack the cognitive capacity to recognize and respond to hypoglycemic symptoms, placing them at greater risk for hypoglycemia and its sequelae. In addition, extensive evidence indicates that near-normalization of blood glucose levels is seldom attainable in children and adolescents after the honeymoon (remission) period. The A1C level achieved in the "intensive" adolescent cohort of the DCCT group was Ͼ1% higher than that achieved for older patients and current ADA recommendations for patients in general (130) .
In selecting glycemic goals, the benefits of achieving a lower A1C must be weighed against the unique risks of hypoglycemia and the disadvantages of targeting a higher, although more achievable goal that may not promote optimal longterm health outcomes. Age-specific glycemic and A1C goals are presented in iv. Retinopathy Although retinopathy most commonly occurs after the onset of puberty and after 5-10 years of diabetes duration, it has been reported in prepubertal children and with diabetes duration of only 1-2 years. Referrals should be made to eye care professionals with expertise in diabetic retinopathy, an understanding of the risk for retinopathy in the pediatric population, as well as experience in counseling the pediatric patient and family on the importance of early prevention/ intervention.
Recommendations
• The first ophthalmologic examination should be obtained once the child is 10 years of age or older and has had diabetes for 3-5 years. (E) • After the initial examination, annual routine follow-up is generally recommended. Less frequent examinations may be acceptable on the advice of an eye care professional. (E) c. Other issues. A major issue deserving emphasis in this age-group is that of "adherence." No matter how sound the medical regimen, it can only be as good as the ability of the family and/or individual to implement it. Family involvement in diabetes remains an important component of optimal diabetes management throughout childhood and into adolescence. Health care providers who care for children and adolescents, therefore, must be capable of evaluating the behavioral, emotional, and psychosocial factors that interfere with implementation and then must work with the individual and family to resolve problems that occur and/or to modify goals as appropriate.
Since a sizable portion of a child's day is spent in school, close communication with school or day care personnel is essential for optimal diabetes management. Information should be supplied to school personnel, so that they may be made aware of the diagnosis of diabetes in the student and of the signs, symptoms, and treatment of hypoglycemia. In most cases it is imperative that blood glucose testing be performed at the school or day care setting before lunch and when signs or symptoms of abnormal blood glucose levels are present. Many children may require support for insulin administration by either injection or continuous subcutaneous insulin injection (CSII) before lunch (and often also before breakfast) at school or in day care. For further discussion, see the ADA position statement "The Care of Children With Diabetes in the School and Day Care Setting" (131) 2. Type 2 diabetes. Finally, the incidence of type 2 diabetes in children and adolescents has been shown to be increasing, especially in ethnic minority populations (132, 133) . Distinction between type 1 and type 2 diabetes in children can be difficult, since autoantigens and ketosis may be present in a substantial number of patients with otherwise straightforward type 2 diabetes (including obesity and acanthosis nigricans). Such a distinction at the time of diagnosis is critical since treatment regimens, educational approaches, and dietary counsel will differ markedly between the two diagnoses. The ADA consensus statement "Type 2 Diabetes in Children and Adolescents" (8) provides guidance to the prevention, screening, and treatment of type 2 diabetes, as well as its comorbidities in young people.
B. Preconception care
Major congenital malformations remain the leading cause of mortality and serious morbidity in infants of mothers with type 1 and type 2 diabetes. Observational studies indicate that the risk of malformations increases continuously with increasing maternal glycemia during the first 6 -8 weeks of gestation, as defined by firsttrimester A1C concentrations. There is no threshold for A1C values above which the risk begins or below which it disappears. However, malformation rates above the 1-2% background rate seen in nondiabetic pregnancies appear to be limited to pregnancies in which first trimester A1C concentrations are Ͼ1% above the normal range.
Preconception care of diabetes appears to reduce the risk of congenital malformations. Five nonrandomized studies have compared rates of major malformations in infants between women who participated in preconception diabetes care programs and women who initiated intensive diabetes management after they were already pregnant. The preconception care programs were multidisciplinary and designed to train patients in diabetes self-management with diet, intensified insulin therapy, and SMBG. Goals were set to achieve normal blood glucose concentrations, and Ͼ80% of subjects achieved normal A1C concentrations before they became pregnant (134 -138) . In all five studies, the incidence of major congenital malformations in women who participated in preconception care (range 1.0 -1.7% of infants) was much lower than the incidence in women who did not participate (range 1.4 -10.9% of infants). One limitation of these studies is that participation in preconception care was self-selected by patients rather than randomized. Thus, it is impossible to be certain that the lower malformation rates resulted fully from improved diabetes care. Nonetheless, the overwhelming evidence supports the concept that malformations can be reduced or prevented by careful management of diabetes before pregnancy.
Planned pregnancies greatly facilitate preconception diabetes care. Unfortunately, nearly two-thirds of pregnancies in women with diabetes are unplanned, leading to a persistent excess of malformations in infants of diabetic mothers. To minimize the occurrence of these devastating malformations, standard care for all women with diabetes who have childbearing potential should include 1) education about the risk of malformations associated with unplanned pregnancies and poor metabolic control and 2) use of effective contraception at all times, unless the patient is in good metabolic control and actively trying to conceive.
Women contemplating pregnancy need to be seen frequently by a multidisciplinary team experienced in the management of diabetes before and during pregnancy. Teams may vary but should include a diabetologist, an internist or a family physician, an obstetrician, a diabetes educator, a dietitian, a social worker, and other specialists as necessary. The goals of preconception care are to 1) integrate the patient into the management of her diabetes, 2) achieve the lowest A1C test results possible without excessive hypoglycemia, 3) assure effective contraception until stable and acceptable glycemia Position Statement is achieved, and 4) identify, evaluate, and treat long-term diabetic complications such as retinopathy, nephropathy, neuropathy, hypertension, and CAD.
For further discussion, see the ADA technical review and position statement on this subject (139, 140) .
Recommendations
• A1C levels should be normal or as close to normal as possible (Ͻ1% above the upper limits of normal) in an individual patient before conception is attempted.
(B) • All women with diabetes and childbearing potential should be educated about the need for good glucose control before pregnancy. They should participate in family planning. (E) • Women with diabetes who are contemplating pregnancy should be evaluated and, if indicated, treated for diabetic retinopathy, nephropathy, neuropathy, and CVD. (E) • Among the drugs commonly used in the treatment of patients with diabetes, statins are pregnancy category X and should be discontinued before conception if possible. ACE inhibitors and ARBs are category C in the first trimester (maternal benefit may outweigh fetal risk in certain situations) but category D in later pregnancy and should generally be discontinued before pregnancy. Among the oral antidiabetic agents, metformin and acarbose are classified as category B and all others as category C; potential risks and benefits of oral antidiabetic agents in the preconception period must be carefully weighed, recognizing that sufficient data are not available to establish the safety of these agents in pregnancy. They should generally be discontinued in pregnancy. (E)
C. Older individuals
Diabetes is an important health condition for the aging population; at least 20% of patients over the age of 65 years have diabetes. The number of older individuals with diabetes can be expected to grow rapidly over the coming decades. A recent publication, "Guidelines for Improving the Care of the Older Person with Diabetes," (141) contains evidence-based guidelines produced in conjunction with the American Geriatric Society. This document contains an excellent discussion of this area, and specific guidelines and language from it have been incorporated below. Unfortunately, there are no longterm studies in individuals Ͼ65 years of age demonstrating the benefits of tight glycemic control, blood pressure, and lipid control. Older individuals with diabetes have higher rates of premature death, functional disability, and coexisting illnesses such as hypertension CHD, and stroke than those without diabetes.
Older adults with diabetes are also at greater risk than other older adults for several common geriatric syndromes, such as polypharmacy, depression, cognitive impairment, urinary incontinence, injurious falls, and persistent pain. The care of older adults with diabetes is complicated by their clinical and functional heterogeneity. Some older individuals developed diabetes in middle age and face years of comorbidity; others who are newly diagnosed may have had years of undiagnosed comorbidity or few complications from the disease. Some older adults with diabetes are frail and have other underlying chronic conditions, substantial diabetes-related comorbidity, or limited physical or cognitive functioning, but other older adults with diabetes have little comorbidity and are active. Life expectancies are also highly variable for this population. Clinicians caring for older adults with diabetes must take this heterogeneity into consideration when setting and prioritizing treatment goals.
All this having been said, patients who can be expected to live long enough to reap the benefits of long-term intensive diabetes management (ϳ10 years) and who are active, cognitively intact, and willing to undertake the responsibility of self-management should be encouraged to do so and be treated using the stated goals for younger adults with diabetes.
There is good evidence from middleaged and older adults suggesting that multidisciplinary interventions that provide education on medication use, monitoring, and recognizing hypo-and hyperglycemia can significantly improve glycemic control. Although control of hyperglycemia is important, in older individuals with diabetes, greater reductions in morbidity and mortality may result from control of all cardiovascular risk factors rather than from tight glycemic control alone. There is strong evidence from clinical trials of the value of treating hypertension in the elderly. There is less evidence for lipid-lowering and aspirin therapy, although as diabetic patients have such an elevated risk for CVD, aggressive management of lipids and aspirin use when not contraindicated are reasonable interventions.
As noted above, for patients with advanced diabetes complications, lifelimiting comorbid illness, or cognitive or functional impairment, it is reasonable to set less intensive glycemic target goals. These patients are less likely to benefit from reducing the risk of microvascular complications and more likely to suffer serious adverse effects from hypoglycemia. Patients with poorly controlled diabetes may be subject to acute complications of diabetes, including hyperglycemic hyperosmolar coma. Older patients can be treated with the same drug regimens as younger patients, but special care is required in prescribing and monitoring drug therapy. Metformin is often contraindicated because of renal insufficiency or heart failure. Sulfonylureas and other insulin secretagogues can cause hypoglycemia. Insulin can also cause hypoglycemia as well as require good visual and motor skills and cognitive ability of the patient or a caregiver. Thiazolidinediones should not be used in patients with CHF (New York Heart Association [NYHA] Class III and IV). Drugs should be started at the lowest dose and titrated up gradually until targets are reached or side effects develop. As well as regards blood pressure and lipid management, the potential benefits must always be weighed against potential risks.
VIII. DIABETES CARE IN SPECIFIC SETTINGS
A. Diabetes care in the hospital The management of diabetes in the hospital is extensively reviewed in the ADA Technical Review, "Management of diabetes and hyperglycemia in hospitals" by Clement et al. (142) . This review forms the basis for these guidelines. In addition, the American Association of Clinical Endocrinologists held a conference on this topic (143) , and the recommendations from this meeting (144) were also carefully reviewed and discussed in the formulation of the guidelines, which follow. The management of diabetes in the hospital is generally considered secondary in importance compared with the condition that prompted admission.
Patients with hyperglycemia fall into three categories:
• Medical history of diabetes: diabetes has been previously diagnosed and acknowledged by the patient's treating physician.
• Unrecognized diabetes: hyperglycemia (fasting blood glucose 126 mg/dl or random blood glucose 200 mg/dl) occurring during hospitalization and confirmed as diabetes after hospitalization by standard diagnostic criteria, but unrecognized as diabetes by the treating physician during hospitalization.
• Hospital-related hyperglycemia: hyperglycemia (fasting blood glucose 126 mg/dl or random blood glucose 200 mg/dl) occurring during the hospitalization that reverts to normal after hospital discharge.
The prevalence of diabetes in hospitalized adult patients is not precisely known. In the year 2000, 12.4% of hospital discharges in the U.S. listed diabetes as a diagnosis. The prevalence of diabetes in hospitalized adults is conservatively estimated at 12-25%, depending on the thoroughness used in identifying patients. Patients presenting to hospitals may have unrecognized diabetes or hospital-related hyperglycemia. Using the A1C test may be a valuable case-finding tool for identifying diabetes in hospitalized patients. A rapidly growing body of literature supports targeted glucose control in the hospital setting with potential for improved mortality, morbidity, and health care economic outcomes. Hyperglycemia in the hospital may result from stress, decompensation of type 1 diabetes, type 2 diabetes, or other forms of diabetes and/or may be iatrogenic due to administration or withholding of pharmacologic agents, including glucocorticoids, vasopressors, etc. Distinction between decompensated diabetes and stress hyperglycemia is often not made.
Blood glucose targets
a. General medicine and surgery. Observational studies suggest an association between hyperglycemia and increased mortality. General medical and surgical patients with a blood glucose value(s) Ͼ220 mg/dl (12.2 mmol/l) have higher infection rates (145) .
When admissions on general medicine and surgery units were studied, patients with new hyperglycemia had significantly increased in-hospital mortality than patients with known diabetes. In addition, length of stay was higher for the new hyperglycemia group, and both the patients with new hyperglycemia and those with known diabetes were more likely to require intensive care unit (ICU) care and transitional or nursing home care. Better outcomes were demonstrated in patients with fasting and admission blood glucose Ͻ126 mg/dl (7 mmol/l) and all random blood glucose levels Ͻ200 mg/dl (11.1 mmol/l) (146) .
b. CVD and critical care. The relationship of blood glucose levels and mortality in the setting of acute myocardial infarction (AMI) has been reported. A metaanalysis 15 previously published studies comparing in-hospital mortality and CHF in both hyper-and normoglycemic patients with and without diabetes. In subjects without known diabetes whose admission blood glucose was 109.8 mg/dl (6.1 mmol/l), the relative risk for inhospital mortality was increased significantly. When diabetes was present and admission glucose was 180 mg/dl (10 mmol/l), risk of death was moderately increased compared with patients who had diabetes but no hyperglycemia on admission (147) . In another study (148) , admission blood glucose values were analyzed in consecutive patients with AMI. Analysis revealed an independent association of admission blood glucose and mortality. The 1-year mortality rate was significantly lower in subjects with admission plasma glucose Ͻ100.8 mg/dl (5.6 mmol/l) than in those with plasma glucose 199.8 mg/dl (11 mmol/l). Finally, in the first Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study, (51,149) insulinglucose infusion followed by subcutaneous insulin treatment in diabetic patients with AMI was examined. Intensive subcutaneous insulin therapy for 3 or more months improved long-term survival (51) . Mean blood glucose in the intensive insulin intervention arm was 172.8 mg/dl (9.6 mmol/l) (vs. 210.6 mg/dl [11.7 mmol/l] in the "conventional" group). The broad range of blood glucose levels within each arm limits the ability to define specific blood glucose target thresholds.
c. Cardiac surgery. Attainment of targeted glucose control in the setting of cardiac surgery is associated with reduced mortality and risk of deep sternal wound infections in cardiac surgery patients with diabetes (150, 151) and supports the concept that perioperative hyperglycemia is an independent predictor of infection in patients with diabetes (152) , with the lowest mortality in patients with blood glucose Ͻ150 mg/dl (8.3 mmol/l) (150, 153) .
d. Critical care. A mixed group of patients with and without diabetes admitted to a surgical ICU were randomized to receive intensive insulin therapy (target blood glucose 80 -110 mg/dl [4.4 -6.1]) The mean blood glucose of 103 mg/dl (5.7 mmol/l) had reduced mortality during the ICU stay and decreased overall in hospital mortality (52) . Subsequent analysis demonstrated that for each 20 mg/dl (1.1 mmol/l), glucose was elevated Ͼ100 mg/dl (5.5 mmol/l), and the risk of ICU death increased. Hospital and ICU survival were linearly associated with ICU glucose levels, with the highest survival rates occurring in patients achieving an average blood glucose Ͻ110 mg/dl (6.1 mmol/l).
e. Acute neurological disorders. Hyperglycemia is associated with worsened outcomes in patients with acute stroke and head injury, as evidenced by the large number of observational studies in the literature (154 -156) A meta-analysis identified an admission blood glucose Ͼ110 mg/dl (6.1 mmol/l) for increased mortality for acute stroke (157) .
Treatment options
a. Oral diabetes agents. No large studies have investigated the potential roles of various oral agents on outcomes in hospitalized patients with diabetes. While the various classes of oral agents are commonly used in the outpatient setting with good response, their use in the inpatient setting presents some specific issues.
• Sulfonylureas and meglitinides-The long action and predisposition to hypoglycemia in patients not consuming their normal nutrition serve as relative contraindications to routine use of sulfonylureas in the hospital for many patients (158). Sulfonylureas do not generally allow rapid dose adjustment to meet the changing inpatient needs. Sulfonylureas also vary in duration of action between individuals and likely vary in the frequency with which they induce hypoglycemia While the two available meglitinides, repaglinide and neteglinide, theoretically would produce less hypoglycemia than sulfonyl-ureas, lack of clinical trial data for these agents would preclude their use.
• Metformin-The major limitation to metformin use in the hospital is a number of specific contraindications to its use, many of which occur in the hospital. All of these contraindications relate to lactic acidosis, a potentially fatal complication of metformin therapy. The most common risk factors for lactic acidosis in metformin-treated patients are cardiac disease, including CHF, hypoperfusion, renal insufficiency, old age, and chronic pulmonary disease (159) . Recent evidence continues to indicate that lactic acidosis is a rare complication, despite the relative frequency of risk factors (160) . However, in the hospital, where the risk for hypoxia, hypoperfusion, and renal insufficiency is much higher, it still seems prudent to avoid the use of metformin in most patients.
• Thiazolidinediones-Thiazolidinediones are not suitable for initiation in the hospital because of their delayed onset of effect. In addition, they do increase intravascular volume, a particular problem in those predisposed to CHF and potentially a problem for patients with hemodynamic changes related to admission diagnoses (e.g., acute coronary ischemia) or interventions common in hospitalized patients.
In summary, each of the major classes of oral agents has significant limitations for inpatient use. Additionally, they provide little flexibility or opportunity for titration in a setting where acute changes demand these characteristics. Therefore, insulin, when used properly, may have many advantages in the hospital setting.
b. Insulin. The inpatient insulin regimen must be matched or tailored to the specific clinical circumstance of the individual patient. A recent meta-analysis concluded that insulin therapy in critically ill patients had a beneficial effect on short-term mortality in different clinical settings (161) .
• Subcutaneous insulin therapySubcutaneous insulin therapy may be used to attain glucose control in most hospitalized patients with diabetes. The components of the daily insulin dose requirement can be met by a variety of types of insulin, depending on the particular hospital situation. Subcutaneous insulin therapy is subdivided into programmed or scheduled insulin and supplemental or correction-dose insulin. Correction-dose insulin therapy is an important adjunct to scheduled insulin, both as a dose-finding strategy and as a supplement when rapid changes in insulin requirements lead to hyperglycemia. If correction doses are frequently required, it is recommended that the appropriate scheduled insulin doses be increased the following day (162) to accommodate the increased insulin needs. There are no studies comparing human regular insulin with rapid-acting analogues for use as correction-dose insulin. However, due to the longer duration with human regular insulin, there is a greater risk of "insulin stacking" when the usual next blood glucose measurement is performed 4 -6 h later.
The traditional sliding scale insulin regimens, usually consisting of regular insulin without any intermediate or longacting insulin, have been shown to be ineffective (162) (163) (164) . Problems cited with sliding scale insulin regimens are that the sliding scale regimen prescribed on admission is likely to be used throughout the hospital stay without modification (162) . Second, sliding scale insulin therapy treats hyperglycemia after it has already occurred, rather than preventing the occurrence of hyperglycemia. This "reactive" approach can lead to rapid changes in blood glucose levels, exacerbating both hyperglycemia and hypoglycemia.
• Intravenous insulin infusion-The only method of insulin delivery specifically developed for use in the hospital is continuous intravenous infusion, using regular crystalline insulin. There is no advantage to using insulin lispro or aspart in an intravenous insulin infusion. • Transition from intravenous to subcutaneous insulin therapy-There are no specific clinical trials examining how to best transition from intravenous to subcutaneous insulin or which patients with type 2 diabetes may be transitioned to oral agents. For those who will require subcutaneous insulin, it is necessary to administer short-or rapidacting insulin subcutaneously 1-2 h before discontinuation of the intravenous insulin infusion. An intermediate or long-acting insulin must be injected 2-3 h before discontinuing the insulin infusion. In transitioning from intravenous insulin infusion to subcutaneous therapy, the caregiver may order subcutaneous insulin with appropriate duration of action to be administered as a single dose or repeatedly to maintain basal effect until the time of day when the choice of insulin or analog preferred for basal effect normally would be provided.
3. Self-management in the hospital. (167) . Additional triggering events leading to iatrogenic hypoglycemia include sudden reduction of corticosteroid dose, altered ability of the patient to self-report symptoms, reduction of oral intake, emesis, new NPO status, reduction of rate of administration of intravenous dextrose, and unexpected interruption of enteral feedings or parenteral nutrition. Altered consciousness from anesthesia may also alter typical hypoglycemic symptoms. Despite the preventable nature of many inpatient episodes of hypoglycemia, institutions are more likely to have nursing protocols for the treatment of hypoglycemia than for its prevention 5. Diabetes care providers. Diabetes management may be offered effectively by primary care physicians or hospitalists, but involvement of appropriately trained specialists or specialty teams may reduce length of stay, improve glycemic control, and improve outcomes (168 -171) . In the care of diabetes, implementation of standardized order sets for scheduled and correction-dose insulin may reduce reliance on sliding scale management. A team approach is needed to establish hospital pathways. To implement intravenous infusion of insulin for the majority of patients having prolonged NPO status, hospitals will need multidisciplinary support for using insulin infusion therapy outside of critical care units. 6. DSME. Teaching diabetes selfmanagement to patients in hospitals is a difficult and challenging task. Patients are hospitalized because they are ill, under increased stress related to their hospitalization and diagnosis, and in an environment that is not conducive to learning. Ideally, people with diabetes should be taught at a time and place conducive to learning: as an outpatient in a nationally recognized program of diabetes education classes.
For the hospitalized patient, diabetes "survival skills" education is generally considered a feasible approach. Patients are taught sufficient information to enable them to go home safely. Those newly diagnosed with diabetes or who are new to insulin and or blood glucose monitoring need to be instructed before discharge to help ensure safe care upon returning home. Those patients hospitalized because of a crisis related to diabetes management or poor care at home need education to hopefully prevent subsequent episodes of hospitalization. 7. MNT. Even though hospital diets continue to be ordered by calorie levels based on the "ADA diet," it has been recommended that the term "ADA diet" no longer be used (172). Since 1994, the ADA has not endorsed any single meal plan or specified percentages of macronutrients. Current nutrition recommendations advise individualization based on treatment goals, physiologic parameters, and medication usage.
Because of the complexity of nutrition issues, it is recommended that a registered dietitian, knowledgeable and skilled in MNT, serve as the team member who provides MNT. The dietitian is responsible for integrating information about the patient's clinical condition, eating, and lifestyle habits and for establishing treatment goals in order to determine a realistic plan for nutrition therapy (172). 8. Bedside blood glucose monitoring. Implementing intensive diabetes therapy in the hospital setting requires frequent and accurate blood glucose data. This measure is analogous to an additional "vital sign" for hospitalized patients with diabetes. Bedside glucose monitoring using capillary blood has advantages over laboratory venous glucose testing because the results can be obtained rapidly at the "point of care," where therapeutic decisions are made. For this reason, the terms bedside and point-of-care glucose monitoring are used interchangeably.
For patients who are eating, com- An adequate number of school personnel should be trained in the necessary diabetes procedures (e.g., blood glucose monitoring and insulin and glucagon administration) and in the appropriate response to high and low blood glucose levels. This will ensure that at least one adult is present to perform these procedures in a timely manner while the student is at school, on field trips, and during extracurricular activities or other schoolsponsored events. These school personnel need not be health care professionals.
The student with diabetes should have immediate access to diabetes supplies at all times, with supervision as needed. A student with diabetes should be able to obtain a blood glucose level and respond to the results as quickly and conveniently as possible, minimizing the need for missing instruction in the classroom. Accordingly, a student who is capable of doing so should be permitted to monitor his or her blood glucose level and take appropriate action to treat hypoglycemia in the classroom or anywhere the student is in conjunction with a school activity. The student's desire for privacy during testing and should also be accommodated. The concept of specialized residential and day camps for children with diabetes has become widespread throughout the U.S. and many other parts of the world. The mission of camps specialized for children and youth with diabetes is to allow for a camping experience in a safe environment. An equally important goal is to enable children with diabetes to meet and share their experiences with one another while they learn to be more personally responsible for their disease. For this to occur, a skilled medical and camping staff must be available to ensure optimal safety and an integrated camping/educational experience. The diabetes camping experience is short term and is most often associated with increased physical activity relative to that experienced while at home. Thus, goals of glycemic control are more related to the avoidance of extremes in blood glucose levels than to the optimization of intensive glycemic control while away at camp.
Recommendations
Each camper should have a standardized medical form completed by his/her family and the physician managing the diabetes that details the camper's past medical history, immunization record, and diabetes regimen. Reception screening should emphasize patient safety. In particular, rapid identification of all insulin-treated individuals with diabetes is essential in order to identify those at highest risk for hypoand hyperglycemia and DKA. All insulintreated patients should have a capillary blood glucose (CBG) determination within 1-2 h of arrival. Patients with a diagnosis of diabetes should have a complete medical history and physical examination by a licensed health care provider with prescriptive authority in a timely manner. It is essential that medication and MNT be continued without interruption upon entry into the correctional system, as a hiatus in either medication or appropriate nutrition may lead to either severe hypo-or hyperglycemia.
All patients must have access to prompt treatment of hypo-and hyperglycemia. Correctional staff should be trained in the recognition and treatment of hypo-and hyperglycemia, and appropriate staff should be trained to administer glucagon. Institutions should implement a policy requiring staff to notify a physician of all CBG results outside of a specified range, as determined by the treating physician.
Correctional institutions should have systems in place to ensure that insulin administration and meals are coordinated to prevent hypo-and hyperglycemia, taking into consideration the transport of patients off-site and the possibility of emergency schedule changes.
Monitoring of CBG is a strategy that allows caregivers and people with diabetes to evaluate diabetes management regimens. The frequency of monitoring will vary by patients' glycemic control and diabetes regimens. Policies and procedures should be implemented to ensure that the health care staff has adequate knowledge and skills to direct the management and education of individuals with diabetes.
Patients in jails may be housed for a short period of time before being transferred or released, and it is not unusual for patients in prison to be transferred within the system several times during their incarceration. Transferring a patient with diabetes from one correctional facility to another requires a coordinated effort as does planning for discharge. This discrimination is often based on apprehension that the person with diabetes may present a safety risk to the employer or to the public-a fear sometimes based on misinformation or lack of up-to-date knowledge about diabetes. Perhaps the greatest concern is that hypoglycemia will cause sudden unexpected incapacitation. However, most people with diabetes can manage their condition in such a manner that there is minimal risk of incapacitation from hypoglycemia. Because the effects of diabetes are unique to each individual, it is inappropriate to consider all people with diabetes the same. People with diabetes should be individually considered for employment based on the requirements of the specific job. Factors to be weighed in this decision include the individual's medical condition, treatment regimen (MNT, oral glucose-lowering agent, and/or insulin), and medical history, particularly in regard to the occurrence of incapacitating hypoglycemic episodes.
Recommendation
• People with diabetes should be individually considered for employment based on the requirements of the specific job and the individual's medical condition, treatment regimen, and medical history. (E)
X. THIRD-PARTY REIMBURSEMENT FOR DIABETES CARE, SELF-MANAGEMENT EDUCATION, AND SUPPLIES (176)
To achieve optimal glucose control, the person with diabetes must be able to access health care providers who have expertise in the field of diabetes. Treatments and therapies that improve glycemic control and reduce the complications of diabetes will also significantly reduce health care costs. Access to the integral components of diabetes care, such as health care visits, diabetes supplies and medications, and self-management education, is essential. All medications and supplies, such as syringes, strips, and meters, related to the daily care of diabetes must also be reimbursed by third-party payers.
It is recognized that the use of formularies, prior authorization, and related provisions, such as competitive bidding, can manage provider practices as well as costs to the potential benefit of payors and patients. However, any controls should ensure that all classes of antidiabetic agents with unique mechanisms of action and all classes of equipment and supplies designed for use with such equipment are available to facilitate achieving glycemic goals and to reduce the risk of complications. To reach diabetes treatment goals, practitioners should have access to all classes of antidiabetic medications, equipment, and supplies without undue controls. Without appropriate safeguards, these controls could constitute an obstruction of effective care.
Medicare and many other third-party payors cover DSMT and MNT. The qualified beneficiary, who meets the diagnostic criteria and medical necessity, can receive an initial benefit of 10 h of DSMT and 3 h of MNT with a potential total of 13 h of initial education, as long as the services are not provided on the same date. However, not all Medicare beneficiaries with a diagnosis of diabetes will qualify for both MNT and DSMT benefits. For more information on Medicare policy including follow-up benefits, go to the following link: http://www.diabetes.org/ for-health-professionals-and-scientists/ recognition/dsmt-mntfaqs.jsp. 
XI. STRATEGIES FOR IMPROVING DIABETES CARE
The implementation of the standards of care for diabetes has been suboptimal in most clinical settings. A recent report (177) indicated that only 37% of adults with diagnosed diabetes achieved an A1C of Ͻ7%, only 36% had a blood pressure Ͻ130/80 and just 48% had a cholesterol level Ͻ200 mg/dl. Most distressing was that only 7.3% of diabetes subjects achieved all three treatment goals. While numerous interventions to improve adherence to the recommended standards have been implemented, the challenge of providing uniformly effective diabetes care has thus far defied a simple solution. A major contributor to suboptimal care is a delivery system that too often is fragmented, lacks clinical information capabilities, often duplicates services, and is poorly designed for the delivery of chronic care. The Institute of Medicine (IOM) has called for changes so that delivery systems provide care that is evidence based, patient centered, and systems oriented and takes advantage of information technologies that foster continuous quality improvement. Collaborative, multidisciplinary teams should be best suited to provide such care for people with chronic conditions like diabetes and to empower patients' performance of appropriate self-management. Alterations in reimbursement that reward the provision of quality care as defined by the attainment of quality measures developed by such activities as the ADA/NCQA Diabetes Provider Recognition Program will also be required to achieve desired outcome goals.
The NDEP recently launched a new online resource to help health care professionals better organize their diabetes care. The www.betterdiabetescare.nih.gov website should help users design and implement more effective health care delivery systems for those with diabetes.
In recent years, numerous health care organizations, ranging from large health care systems such as the U.S. Veteran's Administration to small private practices, have implemented strategies to improve diabetes care. Successful programs have published results showing improvement in important outcomes such as A1C measurements and blood pressure and lipid determinations as well as process measures such as provision of eye exams. Successful interventions have been focused at the level of health care professionals, delivery systems, and patients. Features of successful programs reported in the literature include:
• Improving health care professional education regarding the standards of care through formal and informal education programs.
• Delivery of DSME, which has been shown to increase adherence to standard of care.
• Adoption of practice guidelines, with participation of health care professionals in the process. Guidelines should be readily accessible at the point of service, such as on patient charts, in examining rooms, in "wallet or pocket cards," on PDAs, or on office computer systems. Guidelines should begin with a summary of their major recommendations instructing health care professionals what to do and how to do it.
• Use of checklists that mirror guidelines have been successful at improving adherence to standards of care.
• System changes, such as provision of automated reminders to health care professionals and patients, reporting of process and outcome data to providers, and especially identification of patients at risk because of failure to achieve target values or a lack of reported values.
• Quality improvement programs combining Continuous Quality Improvement (CQI) or other cycles of analysis and intervention with provider performance data.
• Practice changes, such as clustering of dedicated diabetes visits into specific times within a primary care practice schedule and/or visits with multiple health care professionals on a single day and group visits.
• Tracking systems either with an electronic medical record or patient registry have been helpful at increasing adherence to standards of care by prospectively identifying those requiring assessments and/or treatment modifications. They likely could have greater efficacy if they suggested specific therapeutic interventions to be considered for a particular patient at a particular point in time (Diabetes Care 26: 942-943, 2003).
• A variety of nonautomated systems such as mailing reminders to patients, chart stickers, and flow sheets have been useful to prompt both providers and patients.
• Availability of case or (preferably) care management services, usually by a nurse. Nurses, pharmacists, and other nonphysician health care professionals using detailed algorithms working under the supervision of physicians and/or nurse education calls have also been helpful. Similarly dietitians using MNT guidelines have been demonstrated to improve glycemic control.
• Availability and involvement of expert consultants, such as endocrinologists and diabetes educators.
Evidence suggests that these individual initiatives work best when provided as components of a multifactorial intervention. Therefore, it is difficult to assess the contribution of each component; however, it is clear that optimal diabetes management requires an organized, systematic approach and involvement of a coordinated team of health care professionals. 
